Deals

Currency
Investment
Eyes on Asia: Merck and BioNTech land Chinese bispecificsEyes on Asia: Merck and BioNTech land Chinese bispecifics

BioXconomy presents the Asia biopharma and healthcare dealmaking and financing news for the week ending 29 November.

byRichard Daverman, Editor
Dec 4, 2024
|
1 Min Read
The ELA'S 2024
Innovation
LSX awards the crème de la crème of dealmakingLSX awards the crème de la crème of dealmaking
byMillie Nelson
Dec 3, 2024
1 Min Read
Shaking hands
Partnering
Picky pharma prone to better proven partners amid dealmaking downturnPicky pharma prone to better proven partners amid dealmaking downturn
byMillie Nelson
Nov 19, 2024
1 Min Read
Money
Investment
Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blastEyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast
byRichard Daverman
Nov 18, 2024
1 Min Read
Money
Investment
Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScriptEyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript
byRichard Daverman
Nov 5, 2024
1 Min Read
Asian currency
Innovation
Eyes on Asia: Astellas bags gene therapy, AZ a lipoprotein, and a Japanese incubatorAstellas bags gene therapy, AZ a lipoprotein, and a Japanese incubator
byRichard Daverman
Oct 21, 2024
1 Min Read
Hubs
Eyes on Asia: News from Sanofi, Bayer, AZ plus the return of VC?
News from Sanofi, Bayer, AZ plus the return of VC?
Sep 29, 2024
|
1 Min Read
byRichard Daverman, Editor
Partnering
To be truly great you need to partner, says J&J
To be truly great you need to partner, says J&J
Sep 25, 2024
|
1 Min Read
byMillie Nelson, Editor
Oncology
Partnering
Bayer and NextRNA: One partnership, two oncology programs
Bayer and NextRNA: One partnership, two oncology programs
Sep 25, 2024
|
1 Min Read
byMillie Nelson, Editor
Hubs
Eyes on Asia: Shinyaku’s $735m DMD deal, Kite turns back in China, and more
Shinyaku’s $735m DMD deal, Kite turns back in China, and more
Sep 23, 2024
|
1 Min Read
byRichard Daverman, Editor
Chinese flag — Photo
Investment
China biopharma faces a pause; how bad is it?
China biopharma mid-2023 market summary
Sep 21, 2024
|
1 Min Read
byRichard Daverman, Editor
Illustration, Science word. Business concept for Study of physical world structure behavior Experimental research — Illustration
Innovation
European drug discovery and development players showcase their science at BIO-Europe 2023
European drug discovery and development players showcase their science
Sep 21, 2024
|
1 Min Read
Partnering
Eyes on Asia: EpimAb sells T-cell, funding for TargetRx, Hygieai on the siRNA march
Eyes on Asia: News from EpimAb, TargetRx, Hygieai
Sep 7, 2024
|
1 Min Read
byRichard Daverman, Editor
Investment
Eyes on Asia: Mulititude out licenses, Huadong bulks up Abs, Merck and Kelun
Eyes on Asia: Multitude out licenses, Huadong bulks up Abs, Merck and Kelun
Aug 25, 2024
|
1 Min Read
byRichard Daverman, Editor
BIO-Europe Spring
Partnering
Competitor today, friend tomorrow: Why partnering is critical for biopharma success
Why partnering is critical for biopharma success
Apr 5, 2024
|
1 Min Read
byMillie Nelson, Editor
Mounajro
Innovation
GLP-1 boom causing pharma players FOMO
GLP-1 boom causing pharma players FOMO
Mar 25, 2024
|
1 Min Read
byMillie Nelson, Editor
Broken heart
Partnering
It’s not me, it’s you! Experts on when you should dump your CDMO
Experts on when you should dump your CDMO
Sep 22, 2023
|
1 Min Read
byMillie Nelson, Editor

News from APAC

Currency
Investment
Eyes on Asia: Merck and BioNTech land Chinese bispecificsEyes on Asia: Merck and BioNTech land Chinese bispecifics
byRichard Daverman
Dec 4, 2024
4 Min Read
Money
Investment
Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blastEyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast
byRichard Daverman
Nov 18, 2024
5 Min Read
Money
Investment
Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScriptEyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript
byRichard Daverman
Nov 5, 2024
3 Min Read
Jan 13 - Jan 15, 2025
An all-inclusive healthcare conference at Hilton Union Square, San Francisco
Register

Recommended

Partnering
Novo’s hunt for genetic med tech drove $600m NanoVation pact
Novo’s hunt for genetic med tech drove $600m NanoVation pact
Plenary at BIO-Europe in Munich
Investment
How industry trends are evolving biotech innovation in 2023
2023 industry trends that helped evolve biotech innovation
three member panel on stage
Innovation
‘Data matters most’ in biotech, and AI is here to help
‘Data matters most’ in biotech, and AI is here to help
Subscribe to Our Newsletters
Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.
Stay Updated